top of page

Deep venous thrombosis (DVT)

Questionnaire/history:

Unilateral limp pain (often below the knee)?

Limb swelling/oedema?

Local tenderness over the venous system?

Skin changes?

- Erythema?

- Warmth?

Venous distension?

Limb circumference > 3 cm versus unaffected leg?

(Note: classic triad of pain, swelling and erythema in < 30%)


Past medical history?

Family history?

Current medication?

Known drug allergies?


Examination:

(Note: DVT cannot be diagnosed or excluded on the basis of clinical symptoms alone)

Limb swelling/oedema?

Local tenderness over the venous system?

Skin changes?

- Erythema?

- Warmth?

Venous distension?

Limb circumference > 3 cm versus unaffected leg?

(Note: classic triad of pain, swelling and erythema in < 30%)


Risk assessment:

Modified Wells score for DVT?

Active cancer (treatment or palliation within 6 months)?

Bedridden recently (> 3 days or major surgery within 12 weeks)?

Calf swelling > 3 cm compared to the other leg (measured 10 cm below tibial tuberosity)?

Collateral (nonvaricose) superficial veins present?

Entire leg swollen?

Localized tenderness along the deep venous system?

Pitting edema, confined to symptomatic leg?

Paralysis, paresis, or recent plaster immobilization of the lower extremity?

Previously documented DVT?

Alternative diagnosis to DVT as likely or more likely (-2)?


Management:

DVT likely - score ≥ 2:

Urgent referral for doppler US (ideally result within 4 hours)

- If imaging cannot be done immediately (< 4 hours) offer interim anticoagulation (see below)

- If imaging confirms DVT offer or continue anticoagulation (see below)

- If DVT is not identified on imaging check D-dimer:

--- If D-dimer is positive, stop anticoagulation (if necessary) and repeat Doppler US in 6-8 days

--- If D-dimer is negative, stop anticoagulation (if necessary) and consider alternative cause

DVT unlikely - score < 2:

Arrange D-dimer test with result available within 4 hours

Consider a point of care test if laboratory test not immediately available

If using point of care D-dimer use quantitative test

Consider age-adjusted D-dimer thresholds for > 50yrs - reduces false positives and unnecessary imaging

If D-dimer test result cannot be obtained within 4 hours offer interim anticoagulation (see below)

- If D-dimer is positive refer urgently for Doppler US and follow protocol above

- If D-dimer is negative then stop anticoagulation and consider alternative diagnosis


Interim anticoagulation:

Choose an anticoagulant that can be continued if DVT is confirmed (see below)

Baseline bloods (FBC, UEs, LFTs, PT, APTT) but do not wait for the results before starting anticoagulation

Anticoagulation for confirmed DVT

Offer anticoagulation for at least 3 months:

1st line:

- Apixaban 10 mg BD for 7 days then 5 mg BD or

- Rivaroxaban 15 mg BD for 21 days then 20 mg OD

If unsuitable:

LMWH for 5 days followed by dabigatran or edoxaban or

LMWH concurrently with warfarin until INR > 2.0 for 2 consecutive readings then warfarin alone


Anticoagulation in special situations:

Extremes of body weight: < 50kg (overdosed) or > 120kg (underdosed)

Monitor therapeutic levels - for most this will mean LMWH/warfarin, however

Recent guidance from ISTH July 2021 has reviewed evidence on DOACs in people with HIGH BMI and concludes 'For treatment of VTE, we suggest that standard doses of rivaroxaban or apixaban are among appropriate anticoagulant options regardless of high BMI and weight'.


Renal impairment (use estimated creatinine clearance NOT eGFR):

Estimated creatinine clearance: 15 -50ml/min:

- Apixaban - no dose adjustment required

- Rivaroxaban - after 21 days use 15 mg OD rather than 20mg

- LMWH concurrently with warfarin until INR > 2.0 for 2 consecutive readings then warfarin alone

Estimated creatinine clearance < 15ml/min:

- LMWH

- LMWH concurrently with warfarin until INR > 2.0 for 2 consecutive readings then warfarin alone


Active cancer:

Offer anticoagulation for 3-6 months

When choosing agent take into account tumour site, interactions with other drugs including cancer drugs and patients bleeding risk

Consider DOAC

If DOAC unsuitable consider LMWH alone or warfarin

For patients in remission follow standard pathway


Antiphospholipid Syndrome:

LMWH concurrently with warfarin until INR> 2.0 for 2 consecutive readings then warfarin alone


Long term anticoagulation

Provoked DVT:

Consider stopping anticoagulation after 3 months (3-6 months for active cancer) if provoking factor is no longer present and clinical course has been uncomplicated

Unprovoked DVT:

Consider continuing anticoagulation beyond 3 months (6 months for active cancer) based on balance of risks of VTE versus bleeding risk. Take patient preference into account

Patients with low bleeding risk are likely to continue to benefit from continuing anticoagulation

HAS-BLED score can be used to assess risk. Consider stopping anticoagulation if score >4 and not modifiable

For patients who decline continued anticoagulation consider Aspirin 75-150 mg OD


Investigation for cancer

Do not offer further investigations for cancer to patients with unprovoked DVT or PE unless they have relevant clinical symptoms or signs

Review medical history, offer examination and baseline bloods


Thrombophilia screening

Consider antiphospholipid antibodies in unprovoked DVT if it is planned to stop anticoagulation

Consider hereditary thrombophilia screen in unprovoked DVT when a first-degree relative has a history of DVT or PE and it is planned to stop anticoagulation

Do not offer testing to those continuing on anticoagulation

Do not offer testing to patients with a provoked DVT


Resource(s):

CKS 2018

NICE NG158

Visual Summary


DOWNLOAD PDF
DOWNLOAD WORD
TERMS & CONDITIONS
PRIVACY POLICY

© 2023 Clinical Templates. All Rights Reserved.

bottom of page